Q1 Earnings Estimate for HRTX Issued By HC Wainwright

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Heron Therapeutics in a report released on Thursday, February 26th. HC Wainwright analyst B. Folkes forecasts that the biotechnology company will post earnings of ($0.03) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Heron Therapeutics’ Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.00 EPS, FY2027 earnings at $0.14 EPS, FY2028 earnings at $0.39 EPS, FY2029 earnings at $0.44 EPS and FY2030 earnings at $0.55 EPS.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. The business had revenue of $40.59 million during the quarter, compared to the consensus estimate of $39.53 million.

HRTX has been the topic of a number of other reports. Jefferies Financial Group reissued a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, November 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.50.

Heron Therapeutics Price Performance

Shares of HRTX opened at $1.20 on Friday. Heron Therapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $2.68. The firm’s 50-day simple moving average is $1.30 and its two-hundred day simple moving average is $1.27. The stock has a market cap of $220.03 million, a PE ratio of -13.33 and a beta of 1.25. The company has a debt-to-equity ratio of 19.89, a quick ratio of 1.78 and a current ratio of 2.56.

Institutional Investors Weigh In On Heron Therapeutics

Several institutional investors have recently modified their holdings of the business. B. Riley Wealth Advisors Inc. bought a new stake in Heron Therapeutics in the 2nd quarter worth about $26,000. Advisory Services Network LLC lifted its stake in Heron Therapeutics by 2,383.4% during the 4th quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 18,114 shares during the period. PKS Advisory Services LLC purchased a new stake in shares of Heron Therapeutics during the 3rd quarter valued at about $25,000. Russell Investments Group Ltd. bought a new stake in shares of Heron Therapeutics in the second quarter worth approximately $43,000. Finally, Jones Financial Companies Lllp grew its stake in shares of Heron Therapeutics by 5,541.2% in the third quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 23,661 shares during the period. 80.01% of the stock is owned by hedge funds and other institutional investors.

Heron Therapeutics News Summary

Here are the key news stories impacting Heron Therapeutics this week:

• Positive Sentiment: Q4 results topped estimates: Heron reported EPS of ($0.02) vs. a ($0.03) consensus and revenue of $40.6M vs. $39.5M expected — evidence of accelerating sales. Heron News Release
• Positive Sentiment: Company issued upbeat FY‑2026 revenue guidance of $173M–$183M (above consensus $171.8M) and adjusted EBITDA guidance of $10M–$20M — guidance that supports the bullish near‑term narrative. Guidance in Press Release
• Positive Sentiment: Analyst support: HC Wainwright maintained a Buy rating and a $6 price target, reflecting conviction in longer‑term upside despite current low share price — a supportive brokerage stance for investor sentiment.
• Neutral Sentiment: Management color and presentation materials released (earnings call, slide deck) provide detail on drivers — ZYNRELEF and APONVIE were cited as the growth engines; investors can review the call for execution updates. Earnings Call Highlights
• Neutral Sentiment: Market coverage: Several outlets summarized the quarter and guidance (Zacks, WTOP) — useful for quick third‑party reads but not new primary data. Zacks Summary
• Negative Sentiment: HC Wainwright trimmed FY‑2027–FY‑2029 (and FY‑2028) EPS forecasts modestly (e.g., FY‑2029 cut to $0.44 from $0.48) — a signal that while near‑term performance is solid, analysts are moderating longer‑term margin/profit expectations.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.